In a new study published in Neuropsychopharmacology Reports, a team of scientists has shed light on the potential of delta opioid receptors to mitigate anxiety through the activation of a specific brain pathway. Their research unveils the intricate mechanisms by which the selective DOP agonist, KNT-127, reduces anxiety-like behavior in mice, marking a significant step towards developing novel treatments for anxiety-related disorders. Delta opioid receptors (DOPs) are a type of opioid receptor, one of several receptors activated by the body’s natural opioid peptides as well as by synthetic and …